Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2023 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
August 14, 2023 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®), in patients with...
August 03, 2023 16:05 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer

WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
May 25, 2023 17:01 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer Favorable preliminary safety profile for XTX101 observed at the recommended...
May 09, 2023 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK, PD, and anti-tumor activity data for XTX101, a tumor-activated, Fc-enhanced...
April 03, 2023 16:05 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
March 02, 2023 16:05 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results

Initial clinical data from XTX101, XTX202 and XTX301 clinical trials anticipated in 2023 XTX202, a tumor-activated IL-2, demonstrated preliminary clinical pharmacodynamic evidence of tumor-selective...
February 27, 2023 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
February 16, 2023 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
February 02, 2023 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...